The presence of preformed donor-specific HLA antibodies detected by Complement-dependent cytotoxicity (CDC) crossmatch assay is associated with a high incidence of hyperacute or accelerated rejection and remains one of the gold standard tests pre-transplant. The standard CDC crossmatch detects IgG1, IgG3, and IgM antibody, i.e. complement fixing, bound to the native viable cell surface of lymphocytes. The crossmatch can be enhanced with the addition of anti-human-globulin to detect non-complement fixing antibodies (IgG2 and IgG4), and sensitivity can be improved with prolonged incubation times.
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
Patel R, Terasaki PI (1969) Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280:735–739PubMedCrossRefGoogle Scholar
Nickerson P, Pochinco D, Karpinski M et al (2004) Class II donor specific antibodies are pathogenic in primary renal allografts. Am J Transplant 4:257CrossRefGoogle Scholar
Eng HS, Bennett G, Humphreys I et al (2008) Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 8:2335–2342PubMedCrossRefGoogle Scholar
Gebel HM, Bray RA, Nickerson P (2003) Pre-transplant assessment of donor-reactive. HLA specific antibodies in renal transplantation: contraindication vs risk. Am J Transplant 3:1488–1500PubMedCrossRefGoogle Scholar